Právní předpis byl sestaven k datu 20.12.2013.
Zobrazené znění právního předpisu je účinné od 20.12.2013 do 19.09.2014.
98
SDĚLENÍ
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx,
xxxxxx xx xxxx x xxxxxxxx sdělení Xxxxxxxxxxxx xxxxxxxxxxxx věcí x. 58/2007 Xx. x. s. x x. 46/2008 Xx. x. x. x xxxxxxxxx sdělení Ministerstva xxxxxxxxxxxx věcí x. 97/2012 Xx. m. x. o Xxxxxxxxxxx xxxxxx proti dopingu xx xxxxxx
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, xx dne 12. xxxxxxxxx 2012 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX oznámeno xxxxxxxxx xxxxxx znění Xxxxxxx X - Xxxxxxx xxxxxxxxxx xxxxx x xxxxx - Mezinárodní xxxxxxxx Mezinárodní xxxxxx xxxxx dopingu ve xxxxxx1).
X xxxxx xxxxxx Přílohy X xxxxxxxx xxxxxxx Parlament Xxxxx republiky.
Xxxx xxxxx Xxxxxxx X xxxxxxxxx v xxxxxxxx x xxxxxxx s xxxxxxx 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2013 x xxxxx xxxx xxxxxxxxx v xxxxxxxx x pro Českou xxxxxxxxx. Dnem xxxxxx xxxxxx znění Přílohy X v xxxxxxxx xxxxxxxx xxxxxx znění Xxxxxxx I Xxxxxxxxxxx xxxxxx xxxxx dopingu xx sportu xxxxxx xx 1. xxxxx 2012 x xxxxxxxxx xxx č. 97/2012 Sb. m. s.
Xxxxxxxx xxxxx Xxxxxxx I x její xxxxxxx xx českého xxxxxx xx xxxxxxxxx současně.
1) Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx xxxxxxx xxx 19. xxxxx 2005 x Xxxxxx xxxx xxxxxxxxx pod č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
XXXXXXX I
XXXXXX XXXXXXXXXX LÁTEK X XXXXX DOPINGU XXX XXX 2013
XXXXXXX ANTIDOPINGOVÝ XXXXX
Xxxxxx xx 1. xxxxx 2013
Xxxxx xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxx xxxxxxx Xxxxxxxx xxxxx xxxxx xxxxxxxxxx xx "Xxxxxxxxxx xxxxx" xxxxx xxxxx xx xxxxxx S1, X2, X4.4, X4.5 x X6(x) a Xxxxxxxxxx xxxxx M1, X2 a X3.
| &xxxx;
XXXXX X METODY XXXXXXXX XXXXX
(XXX XXXXXXX X XXXX XXXXXX)
|
XXXXXXXX XXXXX
X0. XXXXXXXXXXX XXXXX
Jakákoliv xxxxxxxxxxxxx xxxxx, která xxxx xxxxxxxx x xxxxxxxxxxxxx xxxxxxx Xxxxxxx x není xxxxxxxx xxxxxxxxx pro xxxxxxx xxxxxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. léčiva x xxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx výzkumu xxxx xx xxxxxxxx xxxxxxxxxx, xxxxxxxxxx xxxxx, xxxxxxxxxxx xxxx), je xxxxxxxx stále.
S1. XXXXXXXXXX XXXXX
Xxxxxxxxxx xxxxx jsou xxxxxxxx.
1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (XXX):
(x) Xxxxxxxx* AAS, xxxxxxxxxx:
1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3β,17β-xxxx); 1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx); xxxxxxxxx (xxxx-4-xx-3β,17β-xxxx); xxxxxxxxxx; xxxxxxxx; xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx); xxxxxxx (17α-xxxxxxx-17β-xxxxxxxxxxxxxx-4-xxx[2,3-x]xxxxxxxx); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-chloro-17β-hydroxy-17α-methylandrosta-1,4-dien-3-on); xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); xxxxxxxxxxx; ethylestrenol (19-xxx-17α-xxxxx-4-xx-17-xx); xxxxxxxxxxxxxx; formebolon; xxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxxxxx[2,3-x]-xxxxxxx); gestrinon; 4-xxxxxxxxxxxxxxxxxx (4,17β-dihydroxyandrost-4-en-3-on); kalusteron; xxxxxxxxx; xxxxxxxxxx; mesterolon; xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx (2α, 17α-xxxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); xxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx); xxxxxx-1-xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx); methylnortestosteron (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); methyltestosteron; metribolon (xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx); miboleron; xxxxxxxxx; 19-norandrostendion (xxxx-4-xx-3,17-xxxx); xxxxxxxxxx; norethandrolon; xxxxxxxxxxxx; xxxxxxxx; oxandrolon; xxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-hydroxy-5α-androstano [3,2-x]xxxxxxx); quinbolon; xxxxxxxxxx; xxxxxxxxx; 1-xxxxxxxxxxx (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (18α-xxxx-xxxxxx-4,9,11-xxxxx-17β-xx-3-xx); xxxxxxxxx x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx účinky.
(x) Xxxxxxxxx** XXX, xxxxx xxxx podány xxxxxxxx:
Xxxxxxxxxxxxx (xxxxxxx-5-xx-3β,17β-xxxx), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), xxxxxxxxxxxxxxxxxx, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX, 3ß-xxxxxxxxxxxxxx-5-xx-17-xxx), xxxxxxxxxxx x xxxxxx xxxxxxxxxx x isomery, xxx ne s xxxxxxxx xxxxx na xx:
| &xxxx;
5α-xxxxxxxxx-3α,17α-xxxx
|
&xxxx;
5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx)
|
| &xxxx;
5α-xxxxxxxxx-3α,17β-xxxx
|
&xxxx; |
| &xxxx;
5α-xxxxxxxxx-3β,17α-xxxx
|
&xxxx;
xxx-xxxxxxxxxxxxxxxxxx
|
| &xxxx;
5α-xxxxxxxxx-3β,17β-xxxx
|
&xxxx;
xxxxxxxxxxxxxx
|
| &xxxx;
xxxxxxx-4-xx-3α,17α-xxxx
|
&xxxx;
3α-xxxxxxx-5αxxxxxxxxx-17-xx
|
| &xxxx;
xxxxxxx-4-xx-3α,17β-xxxx
|
&xxxx;
3β-xxxxxxx-5αxxxxxxxxx-17-xx
|
| &xxxx;
xxxxxxx-5-xx-3β,17α-xxxx
|
&xxxx;
7α-xxxxxxx-XXXX
|
| &xxxx;
xxxxxxx-5-xx-3α,17α-xxxx
|
&xxxx;
7β-xxxxxxx-XXXX
|
| &xxxx;
xxxxxxx-5-xx-3α,17β-xxxX
|
&xxxx;
7-xxxx-XXXX
|
| &xxxx;
xxxxxxx-5-xx-3β,17α-xxxx
|
&xxxx;
19-xxxxxxxxxxxxxx
|
| &xxxx;
4-xxxxxxxxxxxxx (androst-4-en-3β,17β-diol)
|
19-noretiocholanolon
|
2. Xxxxxxx xxxxxxxxxx xxxxx, zahrnující:
Klenbuterol, xxxxxxxxxx xxxxxxxxxx androgenových xxxxxxxxx (XXXX), xxxxxxx, xxxxxxx, xxxxxxxxxx, xxx xx s xxxxxxxx xxxxx na xx.
| &xxxx;
Xxx xxxxx xxxxxxx xxxx xxxxx: * "exogenní" xx xxxxxxxx x xxxxx, kterou xxxx xxxx xxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxxx. ** "xxxxxxxxx " xx xxxxxxxx k xxxxx, xxxxxx xxxx xxxx xxxxxxxxxx xxxxxxxxx.
|
X2. PEPTIDOVÉ XXXXXXX, XXXXXXX FAKTORY X XXXXXXXX XXXXX
Následující xxxxx a jejich xxxxxxxxxx xxxxxxx xxxx xxxxxxxx:
1. Xxxxx xxxxxxxxxxx xxxxxxxxxxx (např. xxxxxxxxxxxx (XXX), darbepoetin (xXXX), stabilizátory hypoxii xxxxxxxxxxxxxx xxxxxxx (XXX), xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX), xxxxxxxxxxx /Hematide/);
2. Xxxxxxxxxxxxxxxxxx (XX) x Xxxxxxxxxxxx hormon (XX) x mužů;
3. Xxxxxxxxxxxxxx;
4. Xxxxxxx xxxxxx (GH), xxxxxxxxxxxxx xxxxxxx xxxxxxx (FGFs), xxxxxxxxxxxx růstový xxxxxx (XXX), insulinu xxxxxxx xxxxxxx faktor-1 (IGF-1), xxxxxxxxxx xxxxxxx faktory (XXX), xxxxxxx xxxxxx xxxxxxxx x xxxxxxxx xxxxxxxx (XXXX) x xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (XXXX), xxxxxx jako xxxxxxxxx jiné xxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxx xxxx degradaci bílkovin xxxxx, šlach a xxxxxx, krevní xxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxxx xxxx ovlivňující xxxx xxxxxxxxx xxxxxx;
x xxxxx látky x xxxxxxxx chemickou xxxxxxxxxx nebo podobnými xxxxxxxxxxxx účinky.
X3. XXXX2- XXXXXXXX
Xxxxxxx xxxx-2 xxxxxxxx včetně xxxx xxxxxxxxxx optických xxxxxxx (xxxx. x- x l-), xxxx xxxxxxxx xxxxx xxxxxxxxxxx (xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx), xxxxxxxxxxx (xxxxxxxxx 36 xxxxxxxxxx xx 24 xxxxx) a xxxxxxxxxxx xxxxx xxxx podány x xxxxxxxx x xxxxxxx x doporučeným xxxxxxxx xxxxxxx xxxxxxx.
Xxxxxxxxxx salbutamolu x xxxx x xxxxxxxxxxx xxxxx xxx 1000 xx/xx a xxxxxxxxxx xxxxxxxxxxx v moči x koncentraci vyšší xxx 40 xx/xx xxxxxx xxxxxxxxxx za xxxxxxxxx xxxxxxxxxxxx xxxxxxx, xxx xxxx xxxxxxxxxx xx xxxxxxxxx laboratorní xxxxx, xxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx farmakokinetickou xxxxxx, xx xxxxxxxxxx xxxxxxxx byl xxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxx nižší xxx xxxx uvedené maximum.
X4. HORMONOVÉ X XXXXXXXXXXX MODULÁTORY
Zakázané xx xxxxxxxxxxx:
1. Xxxxxxxxxx aromatáz, xxxxxxxxxx:
Xxxxxxxxxxxxxxxx, anastrozol, xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (xxxxxxxxxxxxxxxxx), 4-xxxxxxxxx-3,6,17-xxxxx (6-oxo),exemestan, xxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxx xx s xxxxxxxx xxxxx xx xx.
2. Xxxxxxxxxx xxxxxxxxxx estrogenových xxxxxxxxx (XXXX), zahrnující:
Xxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.
3. Xxxxxxx xxxxxxxxxxxxxx xxxxx xxxxxxxxxx:
Cyklofenil, xxxxxxxxxxx, klomifen, xxx xx x omezením xxxxx xx xx.
4. Látky xxxxxxxxxxxx xxxxxx xxxxxxxxxx včetně xxxxxxxxxx xxxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx ně.
5. Xxxxxxxxxxx xxxxxxxxxx:
x) Xxxxxxxx;
x) Xxxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxxxxxx proliferátory /Peroxisome Xxxxxxxxxxxx Activated Xxxxxxxx δ (XXXXδ) agonists/ (xxxx. XX 1516) x Xxxxxxxx proteinkinasové xxx xxxxxxxxxx XXX x xxxxxxxxxxx s XXXX xxxxx /XXXXδ-XXX-xxxxxxxxx xxxxxxx xxxxxx (XXXX) xxxx agonists/ (xxxx. XXXXX)
X5. XXXXXXXXX X XXXXXXX XXXXXXXXX XXXXX
Xxxxxxxxx látky xxxx xxxxxxxx. Xxxxxxxx:
Xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxx. glycerol, xxxxxxxxxx xxxxxx xxxxxxxx, dextranu, xxxxxxxxxxxxxxxxxx x mannitolu), xxxxxxxxxx a xxxxx xxxxx s xxxxxxxxx xxxxxxxxxxxx xxxxxx. Lokální xxxxxx xxxxxxxxxxxx xxx xxxxx anestézi xxxx xxxxxxxx.
Xxxxxxxxx xxxxxxxx:
Xxxxxxxxxxxx, amilorid, bumetanid, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, xxxxxxxx, kyselina etakrynová, xxxxxxxxx, spironolakton, xxxxxxxx (xxxx. xxxxxxxxxxxxxxxxxx, hydrochlorothiazid, xxxxxxxxxxxxx), triamteren a xxxxx látky s xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx (kromě xxxxxxxxxxxx, xxxxxxxxx a xxxxxxxxx xxxxxx dorzolamidu x xxxxxxxxxxxx, xxxxx xxxxxx xxxxxxxx).
Pro xxxxxxx (Xxx Xxxxxxx, xxxxxxxx Xxxx Xxxxxx) xxxxxxxxxxx xxxxxxxx xxxxx xx xxxxxxxxxx prahovým xxxxxxx (xx. xxxxxxxxxx, xxxxxxxxxx, xxxxxx, xxxxx, xxxxxxx, xxxxxxxxxxxx x pseudoefedrin) xx xxxxxxx s xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx xx xxxxxxxxxx xxxxxxx xxxxxxxxxx Xxxxxxxxxxxx xxxxxxx na xxxx látku xxxxx x xx, která xxx xxxx xxxxxxx xx xxxxxxxxxx nebo xxxxx maskovací xxxxx.
XXXXXXXX XXXXXX
M1. XXXXXXXXXX X KRVÍ X XXXXXXXX XXXXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
1. Xxxxxx xxxx xxxxxxxxxxxxx xxxxxxxxx, homologní xxxx xxxxxxxxxxx xxxx xxxx xxxxxxxxx xxxxxxx a xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx původu xx xxxxxxxxx xxxxxxx.
2. Xxxxx xxxxxxxxx spotřeby, xxxxxxx nebo xxxxxxx xxxxxxx, xxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx (např.krevní xxxxxxxx xxxxxxxx na xxxxxxxxxxx, xxxxxxxxxxxxxxxxxx xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx a xxxxxxxxxxx (XXX13), xxx xx x xxxxxxxx pouze xx xx. Xxxxxxxxxxxx xxxxxxxx xxxxxxxx xxxx.
3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx s xxxx nebo x xxxxxxxx komponentami xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx.
X2. XXXXXXXX X XXXXXXXXX XXXXXXXXXX
Xxxxxxxx xx následující:
1. Xxxxxxxxx, xxxx xxxxx x xxxxxx, xx xxxxxx xxxxxxx xxxxxxxxx x xxxxxxxx Vzorků xxxxxxxxxx xxx Dopingové xxxxxxxx xx zakázané. Xx xxxxxxxx xxxxxx x/xxxx xxxxxx (např. xxxxxxxxxx) xxxx, xxx xx x xxxxxxxx xxxxx na xx.
2. Nitrožilní xxxxxx x/xxxx xxxxxxx více xxx 50 xx xx 6 hodin xxxx xxxxxxxx xxxxx xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxx xxxxxxxxxxxx xxxxxxx xxxx klinických xxxxxxxxxxxxx xxxxx.
X3. XXXXXX XXXXXX
Z xxxxxx xxxxxxxxxx ke xxxxxxx sportovního výkonu xx zakázáno následující:
1. Transfer xxxxxxxxxx xxxxxxx xxxx xxxxxx xxxxxxxx;
2. Xxxxxxx xxxxxxxxxx xxxx geneticky xxxxxxxxxxxxxx xxxxx;
| &xxxx;
XXXXX X XXXXXX XXXXXXXX XXX XXXXXXX
|
Xxxxx xxxxxxxxx X0 xx X5 x X1 xx X3 xxxxxxxxx xxxx xxxx Xxx Xxxxxxx xxxxxxxx x následující xxxxxxx:
XXXXXXXX LÁTKY
X6. XXXXXXXXXXX
Všechna stimulancia xxxxxx všech xxxxxx xxxxxxxxxx optických xxxxxxx (xxxx. x- x x-) jsou zakázaná, x xxxxxxxx xxxxxxxx xxxxxxxxx x xxxxxxx xxxxxx xxxxxxxx použití x stimulancií zahrnutých xx Monitorovacího programu xxx rok 2013*.
Xxxxxxxxxxx zahrnují:
(x) Xxxxxxxxxxxx xxxxxxxxxxx:
Xxxxxxxxx, xxxxxxxxxx, amfetaminil, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxx, dimethylamfetamin, xxxxxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, 4-xxxxxxxxxxxxxx (karfedon), xxxxxxxxxx, xxxxxxxxxxx, xxxxxx, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx (x-), xxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxx, x-xxxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx.
Xxxxxxxxxxxx, xxxxx xxxx výslovně xxxxxxx x tomto xxxxxxxx, xx Xxxxxxxxxxx látkou.
(x) Xxxxxxxxxx stimulancia (xxxxxxxx):
Adrenalin**, xxxxx***, xxxxxxx****, etamivan, etilefrin, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxxx, isomethepten, levmetamfetamin, xxxxxxxxxxxx, xxxxxxxxxxxx****, methylfenidát, xxxxxxxxxxxxxxx (dimetylpentylamin), xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxxxxxxxx, pemolin, pentetrazol, xxxxxxxxxxxxxx, xxxxxxxxxxxxx*****xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, tuaminoheptan a xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
* Následující xxxxx zahrnuté xx Xxxxxxxxxxxxxx programu 2013 (xxxxxxxxx, xxxxxxxxxx, fenylpropanolamin, xxxxxx, nikotin, xxxxxxxxx, xxxxxxxx) xxxxxx považovány xx Xxxxxxxx látky.
** Lokální podání xxxxxxxxxx (xxxx. nosní, xxxx aplikace) xxxx xxxx xxxxxx společně x lokálními xxxxxxxxxx xxxx zakázáno.
*** Xxxxx je zakázaný xxxxx při xxxxxxxxxxx xxxxx než 5 xxxxxxxxxx x 1 xx xxxx.
**** Xxxxxxx x methylefedrin xxxx xxxxxxxx při xxxxxxxxxxx xxxxx než 10 mikrogramů x 1 xx xxxx.
***** Pseudoefedrin xx xxxxxxx, xxxxx xxxx xxxxxxxxxxx v moči xx xxxxx než 150 mikrogramů xx xxxxxxxx
S7. XXXXXXXXX
Xxxxxxxx je xxxxxxxxxxx:
Xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx(xxxxxx), xxxxxxxx x jeho xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxx, xxxxxxxx, oxymorfon, xxxxxxxxxx, xxxxxxx.
X8. XXXXXXXXXXX
Xxxxxxxx (např. xxxxx, xxxxxx x xxxxxxxxx) xxxx xxxxxxxxxx xxxxx9-xxxxxxxxxxxxxxxxxxx (XXX) x xxxxxxxxxxxxxx (xxxx. "Xxxxx" /XXX018, XXX073/ a XX-210) xxxx xxxxxxxx.
X9. XXXXXXXXXXXXXXXXXXXX
Xxxxxxx xxxxxxxxxxxxxxxxxxxx podávané orálně, xxxxxxxx, xxxxxxxxxx xxxx xxxxxxxxxxxxx xxxxxxxx jsou xxxxxxxx.
| &xxxx;
XXXXX ZAKÁZANÉ X XXXXXXXX XXXXXXXX
|
P1. ALKOHOL
Xxxxxxx (xxxxxx) xx xxxxxxxx xxxxx Xxx Xxxxxxx v xxxxxxxxxxxxx xxxxxxxx. Xxxxxxx xx xxxx xxxxxxxx xxxxxxxx xxxxxxxx x/xxxx rozborem xxxx. Xxxxxxx hodnota xxx xxxxxxxx xxxxxxxxxxx xxxxxxxx (xxxxxxxxxxxxx hodnota) xx 0.10 g/l.
∙ Xxxxxxxxxxxx xxxxx (XXX)
∙ Xxxxxx (XXX)
∙ Xxxxxxx xxxxxx a parašutismus(FAI)
∙ Lukostřelba (FITA)
∙ Xxxxxxxxxxx xxxxx (XXX)
∙ Xxxxx xxxxxxxxxx (XXX)
X2. XXXX-XXXXXXXXX
Pokud není xxxxx xxxxxx, xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx Xxx Xxxxxxx x xxxxxxxxxxxxx sportech.
∙ Xxxxxxxxxxxx xxxxx (FIA)
∙ Xxxxxxxx (všechny xxxxxxxxxx) (WCBS)
∙ Xxxx (XXX)
∙ Xxxxxxxxxxx (XXXX, XXX) (xxxxxxxx také Xxxx xxxxxx)
∙ Xxxxxxxx (XXX) - skoky xx xxxxxx x xxxxxxxxxxx lyžování-skoky x X-xxxxx,x xxxxxxxxx U-rampa x "xxx xxx"
∙ Xxxxxxx (XXXX, XXX) (xxxxxxxx také Xxxx soutěž)
∙ Xxxxx (XXX)
Xxxx-xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxx:
Xxxxxxxxxx, xxxxxxxxxx, atenolol, xxxxxxxxx, bisoprolol, xxxxxxx, xxxxxxxxxx, esmolol, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, levobunolol, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxxx, ale xx x xxxxxxxx xxxxx xx xx.
Xxxxxxxxx
Xxxxxx xxxxxxx x. 98/2013 Xx. x. x. xxxxx xxxxxxxxx xxxx 20.12.2013.
Právní xxxxxxx x. 98/2013 Xx. x. x. xxx xxxxxx xxxxxxx xxxxxxxxx č. 47/2014 Sb. m. s. x xxxxxxxxx xx 20.9.2014.
Znění jednotlivých xxxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx xx xxxx xxxxxx xxxxxxxxx xxxxx xxxxx uvedeného xxxxxxxx xxxxxxxx.